Molecule
Etonogestrel is a progestin indicated for prevention of pregnancy in women of reproductive potential for up to 5 years. It is available as implants for subcutaneous use. MedsAcross supplies Etonogestrel for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
NEXPLANON ® is indicated for prevention of pregnancy in women of reproductive potential for up to 5 years. NEXPLANON is a progestin indicated for prevention of pregnancy in women of reproductive potential for up to 5 years.
Source: US FDA prescribing information
The contraceptive effect of NEXPLANON is achieved by suppression of ovulation, increased viscosity of the cervical mucus, and alterations in the endometrium.
Source: US FDA prescribing information
The efficacy of NEXPLANON does not depend on daily, weekly, or monthly administration. All healthcare professionals should receive instruction and training prior to performing insertion and/or removal of NEXPLANON. A single NEXPLANON implant is inserted subdermally just under the skin at the inner side of the non-dominant upper arm. The insertion site is overlying the triceps muscle about 8-10 cm (3-4 inches) from the medial epicondyle of the humerus and 3-5 cm (1.25-2 inches) posterior to (below) the sulcus (groove) between the biceps and triceps muscles. This location is intended to avoid the large blood vessels and nerves lying within and surrounding the sulcus. Inserting an implant more deeply than subdermally (a deep insertion) may preclude palpation and localization, making removal difficult or impossible. NEXPLANON must be inserted by the expiration date stated on the packaging.
Source: US FDA prescribing information
NEXPLANON should not be used in women who have Known or suspected pregnancy Current or past history of thrombosis or thromboembolic disorders Liver tumors, benign or malignant, or active liver disease Undiagnosed abnormal uterine bleeding Known or suspected breast cancer, personal history of breast cancer, or other progestin-sensitive cancer, now or in the past Allergic reaction to any of the components of NEXPLANON Known or suspected pregnancy. Current or past history of thrombosis or thromboembolic disorders. Liver tumors, benign or malignant, or active liver disease. Undiagnosed abnormal uterine bleeding.
Source: US FDA prescribing information
Boxed warning (risk of complications due to improper insertion and removal): Improper insertion of NEXPLANON increases the risk of complications. Proper training prior to first use of NEXPLANON can minimize the risk of improper NEXPLANON insertion. The following information is based on experience with the etonogestrel implants (IMPLANON and/or NEXPLANON), other progestin-only contraceptives, or experience with combination (estrogen plus progestin) oral contraceptives. Insertion and removal complications: Pain, paresthesia, bleeding, hematoma, scarring, infection, or migration to vasculature, including pulmonary vessels, may occur. Symptoms associated with implants in pulmonary vessels include chest pain, dyspnea, cough, or hemoptysis. Surgical interventions may be necessary to remove implants.
Source: US FDA prescribing information
The following adverse reactions reported with the use of hormonal contraception are discussed elsewhere in the labeling: Changes in Menstrual Bleeding Patterns Ectopic Pregnancies Thrombotic and Other Vascular Events Liver Disease Most common (≥10%) adverse reactions reported in clinical trials were change in menstrual bleeding pattern, headache, vaginitis, weight increase, acne, breast pain, abdominal pain, and pharyngitis.
Source: US FDA prescribing information
Consult the labeling of concurrently-used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations. Drugs or herbal products that induce certain enzymes, such as CYP3A4, may decrease the effectiveness of progestin hormonal contraceptives or increase breakthrough bleeding.
Source: US FDA prescribing information
Store NEXPLANON at 20ºC to 25ºC (68ºF to 77ºF), excursions permitted between 15ºC to 30ºC (59ºF to 86ºF). Avoid storing NEXPLANON at temperatures above 30ºC (86ºF).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Etonogestrel, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Nexplanon 68 mg implantSubcutaneous | Organon | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 17 July 2006 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Etonogestrel in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 1 presentations of Etonogestrel and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Etonogestrel, including Nexplanon.
Yes. The US FDA first approved Etonogestrel on 17 July 2006, according to Drugs@FDA.
No listed presentation of Etonogestrel is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Etonogestrel is classified under ATC code G03AC08 (Etonogestrel).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.